Inovio launches late-stage cervical dysplasia trial after FDA lifts hold
Shares in Inovio Pharmaceuticals (NSDQ:INO) jumped more than 10% after it announced that it is launching a Phase III clinical study of its investigational DNA immunotherapy candidate designed to treat cervical dysplasia caused by human papillomavirus.
The moves comes after the FDA lifted a hold that it placed on the clinical program in October last year. At the time, the FDA requested data to support the shelf-life of the disposable parts of Inovio’s Cellectra electroporation device.
Get the full story at our sister site, Drug Delivery Business News.
The post Inovio launches late-stage cervical dysplasia trial after FDA lifts hold appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Food & Drug Administration (FDA) Oncology Wall Street Beat Women's Health Inovio Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Clinical Trials | Genital Warts | Human Papillomavirus (HPV) | Immunotherapy | Study | Women